Table 1.

Synopsis of reviewed trials. In each case, the study acronym is followed by a brief summary of the main conclusions of the trial. The last three studies in the table have recently been submitted for publication. These are “Combination therapy with a long-acting β-agonist and a leukotriene antagonist in moderate asthma” (SLIMSIT) and “Predicting response to inhaled corticosteroid efficacy” (PRICE) through the ACRN and “Acute intermittent management strategies” (AIMS) by the CARE Network.

Trial	Summary
BAGS	Scheduled albuterol usage is neither beneficial nor harmful
SOCS	Salmeterol cannot be used as monotherapy for moderate disease
SLIC	Control gained with salmeterol addition allows ICS dose reduction
BARGE	Genotype at the 16th amino acid residue of the beta2-adrenergic receptor affects the long-term response to albuterol use
DICE	Partial suppression of overnight plasma cortisol levels is a reliable method for comparing ICS side effect potency
MICE	Maximum improvement in FEV1 after a 6 wk ICS trial occurs at lower doses with less HPA-axis suppression than those required to affect airway hyperresponsiveness
IMPACT	Symptom-driven, intermittent use of ICS in mild disease is not associated with increased exacerbation rates
PEAK	ICS are effective in reducing pediatric asthma symptom burden but do not modify asthma natural history
CLIC	More children have an improved FEV1 on ICS than on montelukast
PACT	Low dose fluticasone provides children more asthma control days than does montelukast
SLIMSIT	Compares ICS-salmeterol versus LTRA-salmeterol as controller strategies for moderate asthma
PRICE	Establishes biomarker predictors of short- and long-term ICS responses
AIMS	Compares acute high dose ICS to montelukast or albuterol at the onset of viral upper respiratory tract infections to reduce subsequent asthma symptoms in preschool children